Effects of OCTA-guided PDT in Acute CSC

Effects of Optical Coherence Tomography Angiography-guided Photodynamic Therapy in Acute Central Serous Chorioretinopathy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03497000

Enrollment

Registered

2018-04-12

Start date

2017-09-01

Completion date

2018-03-27

Last updated

2018-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Serous Chorioretinopathy, Tomography, Optical Coherence

Keywords

optical coherence tomography angiography, central serous chorioretinopathy, photodynamic therapy

Brief summary

OCTA-guided PDT is as safe and effective as ICGA-guided PDT in the treatment of acute central serous chorioretinopathy. Or OCTA-guided PDT is more effective than ICGA-guided PDT in the treatment of acute central serous chorioretinopathy, safe as well.

Interventions

PROCEDUREOCTA-guided Photodynamic therapy

Half-dose photodynamic therapy using verteporfin under the guidance of OCTA

PROCEDUREICGA-guided Photodynamic therapy

Half-dose photodynamic therapy using verteporfin under the guidance of ICGA

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Idiopathic detachment of the neurosensory retina with a focal leak at the level of the RPE with FA * Presence of SRF and/or serous pigment epithelial detachment on OCT * Presence of abnormal dilated choroidal vasculature in ICGA

Exclusion criteria

* Patients with other ocular conditions commonly associated with SRF, such as choroidal neovascularization, polypoidal choroidal vasculopathy (PCV), diabetic retinopathy, retinal vascular occlusion, Coat's disease * Any disease that may affect the quality of imaging (quality of OCTA images \< 6), such as cataract, high myopia or nystagmus * History of ocular surgeries including retinal laser * Pregnancy * Any uncontrolled systemic disease * Any condition rendering patients intolerable to image acquisition

Design outcomes

Primary

Measure	Time frame
Number of patients with subretinal fluid resolution on OCT after PDT of two groups	3 months

Secondary

Measure	Time frame
Number of patients with leakage point resolution on FFA after PDT of two groups	3 months
Number of recurrent CSC after PDT of two groups	3 months
BCVA (best corrected visual acuity) at every follow-up of two groups	1 month, 3 months

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026